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ous abstinence rate and intervention costs were estimated. a dynamic population 
model for COPD was used to project the long-term (cost-)effectiveness of one year 
implementation of minimal counseling, intensive counseling and intensive counseling 
plus pharmacotherapy for 50% of the smoking COPD patients compared to usual 
care. Time horizon was 25 years. Uncertainty and one-way sensitivity analyses were 
performed for variations in (the calculation of) the abstinence rates, the type of projec-
tion, intervention costs and discount rates. RESULTS: Nine studies were selected. The 
average 12 months continuous abstinence rates were estimated to be 1.4% for usual 
care, 2.6% for minimal counseling, 6.0% for intensive counseling and 12.3% for 
pharmacotherapy. Compared to usual care, the costs per QALY gained for minimal 
counseling, intensive counseling and intensive counseling plus pharmacotherapy were 
c16,900, c8,200 and c2,400, respectively. Results were most sensitive to variations in 
abstinence rates and discount rates. CONCLUSIONS: Compared to usual care inten-
sive counseling and pharmacotherapy resulted in low costs per QALY gained with 
ratios comparable to results presented for smoking cessation in the general population. 
Compared to intensive counseling alone, intensive counseling plus pharmacotherapy 
was cost saving and dominated the other interventions.
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A COST-UTILITY ANALYSIS FOR TIOTROPIUM BROMIDE IN THE LONG 
TERM TREATMENT OF SPECIFIC SUBGROUPS OF ITALIAN COPD 
PATIENTS
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OBJECTIVES: The UPLIFT trial demonstrated in 5,993 patients with moderate to 
very-severe chronic obstructive pulmonary disease (COPD) that 4 years of tiotropium 
bromide were associated with improvements in lung function, quality of life, and 
exacerbations compared with placebo. The aim of this study is the economic assess-
ment of tiotropium when included in COPD routine care (RC) for speciﬁ c groups of 
Italian COPD patients. METHODS: A probabilistic patient-level simulation Markov 
model was developed over a lifetime horizon, with one-year cycles and a 3.5% annual 
discount rate. Patients were characterized by gender, age, height, smoking status and 
FEV1. FEV1 time trend was modelled based on the decline recorded in UPLIFT. The 
mortality of the general Italian population adjusted by smoking status and FEV1 was 
adopted. Health utilities derived from published Italian studies, while their variation 
from the UPLIFT. Exacerbation rates derived from an Italian observational prospec-
tive study and were adjusted for the relative risk (RR) reported in UPLIFT. Direct 
sanitary costs were considered. Health care resource consumption for RC, exacerba-
tions and SAEs derived from Italian observational studies and were valued according 
to current price and tariffs. Cost-effectiveness was assessed for the overall cohort and 
for subgroups of patients by age, sex, GOLD stage and smoking attitude. RESULTS: 
In the whole cohort, patients treated with tiotropium gained an average (95%CI) 0.50 
(−1.63– −6.27) LYs and 0.42 (−0.25– −3.05) QALYs with respect to RC. The incre-
mental lifetime cost was c3,357 (−c10,669– −c29,820). The incremental cost-effec-
tiveness ratio (ICER) was c7,916 /QALY. In the subgroups analysis the ICER ranged 
from a minimum of c6,627/QALY (females, GOLD III) to a maximum of c13,187/
QALY (age <65 y, GOLD IV). CONCLUSIONS: The inclusion of tiotropium in RC 
for moderate to very severe COPD patients represents good value for money in Italy. 
The analysis across subgroups demonstrated a good stability of the model.
PRS26
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OBJECTIVES: In the Brazilian public health care system, mometasone furoate (MF 
DPI) is not available and budesonide/formoterol (BUD/FF DPI) association is respon-
sible for 86.9% of pharmacy claims for asthma. This study aimed to conduct cost-
effectiveness and budget impact analysis (BIA) of MF versus BUD/FF for adult patients 
with mild to moderate asthma from the public payer perspective. METHODS: A 
decision tree was developed to compare MF and BUD/FF based on indirect comparison 
once head-to-head studies were not available. The ﬁ nal FEV1 values were converted 
into probabilities of hospitalization in the ﬁ rst two years in accordance with observa-
tional evidence of association between FEV1 and exacerbation requiring hospitaliza-
tion. Only direct medical costs were considered and unit costs were obtained from 
Brazilian ofﬁ cial lists. BIA assumed pharmacy claims data from the Ambulatory 
Information System as current scenario (Beclomethasone: 3.1%; BUD: 9.9%; BUD/
FF: 86.9%) and a 20% initial market share for MF in substitution to equivalent doses 
of BUD/FF. RESULTS: Indirect comparison indicated 79 hospitalizations per 1000 
patients for MF and 82 for BUD/FF during the ﬁ rst 2 years of treatment. Total cost 
of treatment was 832BRL and 655BRL per patient for MF200 mcg twice a day (bid) 
and MF400 mcg once a day and 840BRL for BUD/FF 400/12 mcg bid. These ﬁ ndings 
indicated MF as cost-saving in the proposed scenario with ICER of −2.608BRL and 
−61.959BRL per avoided hospitalization for MF200 mcg and MF400 mcg, respec-
tively. The estimated budgetary impact for the ﬁ rst year showed a saving of 
259,346,480BRL for MF 400 mcg and 10,919,299BRL for MF 200 mcg. CONCLU-
SIONS: MF is a clinically effective option to treat mild to moderate asthma and 
indirect comparison showed its clinical and economic beneﬁ t when compared to the 
most used anti-asthma medication in the Brazilian public setting. Further research to 
directly compare both medications and to measure ﬁ nalistic outcomes alongside clini-
cal trials is needed.
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COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL: THE 
CASE FOR ROFLUMILAST IN THE NETHERLANDS
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BACKGROUND: The phosphodiesterase-4 enzyme (PDE4) inhibitor roﬂ umilast is a 
new treatment that targets the underlying inﬂ ammation associated with COPD. When 
approved, roﬂ umilast will be registered as an add-on to bronchodilator treatment in 
adult patients with severe COPD, with a history of frequent exacerbations. a health 
economic (HE) micro-simulation Markov model was used to support its submission 
in the United Kingdom (UK). Pharmaceutical companies can save signiﬁ cantly on the 
process of HE evidence development, if models can be adapted for use in more than 
one country. OBJECTIVES: To transfer an existing UK HE model to the The Neth-
erlands in order to calculate the cost-effectiveness (CE) of roﬂ umilast in patients with 
severe COPD from a societal perspective. METHODS: The model structure was 
adapted to include production loss using the friction cost method, and to separate 
heterogeneity from parameter uncertainty. All input parameters on health care use, 
costs, utilities, and COPD epidemiology were obtained from Dutch sources, except 
for the case-fatality rate of an exacerbation-related hospitalization. a direct compari-
son was made between a combination of a long-acting β2 agonist (LABA) plus 
roﬂ umilast (ROFLU) and LABA alone. a second, indirect comparison was between 
LABA + ROFLU and LABA plus an inhaled corticosteroid (ICS). One-way and proba-
bilistic sensitivity analyses were performed. RESULTS: From a societal perspective, 
the incremental CE ratio (ICER) for LABA + ROFLU compared with LABA alone, 
was c7900. The ICER of LABA + ROFLU versus LABA + ICS was c10,000. The 
probability that LABA + ROFLU was cost-effective when compared with LABA alone 
at a threshold of c20,000 versus LABA was 97%. Compared with LABA + ICS this 
probability was 68.3%. CONCLUSIONS: The original UK model was suitable for 
adaptation to the Dutch setting. The ICERs of roﬂ umilast were below commonly 
referred threshold values of a QALY.
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OBJECTIVES: To estimate the incremental cost-effectiveness of SFC verus montelu-
kast in adult patients with persistent asthma. METHODS: A decision-analytic model 
was developed from a randomized, double-blind, double-dummy, 12-week clinical 
trial were analyzed. Efﬁ cacy end points included, symptom-free days (SFDs) during 
the 12-week period. The study assumed the Mexican health care perspective with costs 
in 2010 US dollars, and hence only direct costs were included in the analysis. Direct 
costs included those related to study drugs, emergency room department visits, 
unscheduled physician visits, and rescue medication. The incremental cost-effective-
ness ratio (ICER), which is the mean difference in average costs divided by the mean 
difference in average effectiveness, was calculated for the effectiveness outcomes 
(SFDs). Issue of uncertainty was addressed by means of a probabilistic Monte Carlo 
simulation, which attributed stochastic distributions to model inputs. RESULTS: 
Treatment with FSC resulted in a signiﬁ cantly greater improvement in the mean 
percentage of symptom-free days compared with MON 48.9 and 21.7 respectively (p 
0.001). In the base case, patients initiated on SFC displayed a 45% reduction in overall 
cost as compared with patients initiated on MON US S186 versus $US258, respec-
tively, respectively). SFC dominated the use of MON because of previously demon-
strated lower incidence of Asthma exacerbations and rescue free days. Sensitivity 
analyses determined that univariate changes in all model variables, including medica-
tion cost, and cost of treating exacerbation, did not impact overall results. a Monte 
Carlo simulation analysis found that use of SFC remains the best overall treatment 
strategy when taking into consideration the potential variance in all model assump-
tions. Compared with MON, SFC is estimated to be both more effective and more 
economically favourable, with a probability of almost 92%. CONCLUSIONS: The 
decision model indicated that use of SFC as treatment in patients with asthma should 
result in lower overall treatment costs relative to the cost of MON.
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OBJECTIVES: To assess the incremental cost-effectiveness of SFC compared with 
MON for the control of persistent asthma in children. METHODS: We conducted an 
economic evaluation on a 12-week prospective randomized open-label parallel-group 
A324 13th Euro Abstracts
comparison of SFC versus MON in children with symptomatic asthma receiving 
inhaled corticosteroids and short-acting β2-agonists. Asthma-related medication, 
unscheduled physician contacts and hospitalizations were collected prospectively. The 
main effectiveness measure was percentage of asthma-controlled week with no short-
acting β2-agonist use during the study period. The analysis was conducted from the 
Mexican health care perspective using 2010 unit cost prices, and only direct costs were 
considered, all costs are reported in US dollar. The model was made fully probabilistic 
to reﬂ ect the joint uncertainty in the model parameters. RESULTS: Over the whole 
treatment period, the median percentages of asthma-controlled weeks were 83.3% in 
the SFC group and 66.7% in the MON group (SFC-MON difference, 16.7%; 95% 
CI, 8.3–16.7; P < 0.001 in favor of SFC). The mean total cost of the SFC regimen was 
US$186 compared with US$271 for the MON regimen. The SFC was the dominant 
strategy (both more effective and less expensive) using the SFC was associated with 
an incremental cost per additional asthma-controlled of $US (513). Probabilistic 
sensitivity analysis tested numerous assumptions about the model cost and efﬁ cacy 
parameters and found that the results were robust to most changes. CONCLUSIONS: 
This analysis demonstrates that, compared with MON, SFC may be cost saving from 
the Mexican health care perspective for the treatment of pediatric patients with 
asthma. SFC provided a reduction in the number of severe exacerbations, frequent 
asthma symptoms and rescue medication use. Incremental cost-effectiveness analysis 
indicated the dominance of SFC because of both lower costs and greater efﬁ cacy.
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Hoogendoorn M, Al M, Rutten-van Mölken MP
Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: Clinical and economic evaluations of the same trial often use different 
statistical analyses and methods to handle missing data. This leads to different results 
for the same health outcome. We aimed to study how the combination of multiple 
imputation (MI) with frequently used advanced methods of clinical analysis affect 
estimates of cost-effectiveness. METHODS: Data from a two-year RCT of an INTER-
disciplinary COMmunity-based COPD management program (INTERCOM) versus 
usual care were used. Five outcomes, SGRQ, EQ-5D, 6MWD, total and severe exac-
erbations measured at 4, 12 and 24 months or continuously (exacerbations) were 
selected. These outcomes were re-analyzed using the same methods used in the clinical 
paper, i.e. with repeated measurement analysis or negative bionomial regression, but 
now after missing data have been imputed using MI. The resulting estimates were 
compared with 1) the estimates in the original clinical paper before MI and 2) the 
estimates obtained after MI based on simple averages before any further statistical 
analyses based on maximum likelihood. RESULTS: A total of 175 patients were 
included in the analysis of which 158 completed the trial. The cost difference of c2751 
between INTERCOM and usual care was kept constant. The number of severe exac-
erbations avoided varied from 0.014 to 0.077 resulting in ICERs from c35,700 to 
c196,500, depending on the approach used. The improvement in SGRQ ranged from 
2.2 to 2.6 units, but the ICERs were all around c1000. The gain in QALYs varied 
from 0.062 with an ICER of c44,400 to 0.085 with an ICER of c32,400 per QALY 
gained. The probability that the INTERCOM program was cost-effective at a thresh-
old value of c50,000 ranged from 56% to 74%. CONCLUSIONS: This study showed 
that the combination of analytic approaches of the clinical and economic evaluations 
does alter the cost-effectiveness ratios.
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IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC 
ASSESSMENT OF COPD TREATMENT BASED ON OBSERVATIONAL 
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OBJECTIVES: To assess cost-effectiveness of adding SAL/FP to routine COPD treat-
ment with Fen/IB. METHODS: Depersonalized patient database was created in mul-
ticenter observational research of severe and very severe COPD. Patients were 
subdivided into two groups: 1- Fen/IB-based therapy without SAL/FP (N = 245); 2- 
Fen/IB-based therapy with SAL/FP (N = 84). Prices of drugs were up to Q1 2010 for 
Moscow city (from Farmexpert market monitoring). Unit cost of inpatient-day, out-
patient-visit and emergency-visit was derived from Moscow city government regula-
tion #290 from 04.2010 (about medicare). Direct medical costs within one year time 
horizon were assessed as health care perspective was taken. RESULTS: Number of 
COPD exacerbations per patient was 3.9 with and 6.8 without SAL/FP. Sum of yearly 
direct medical costs was 31,607 RUB (c832) with and 55,179 RUB (c1452) without 
SAL/FP. Incremental cost per one prevented exacerbation (ICER) was 1237 RUB 
(c32.5). Average cost of treatment of one exacerbation was 8 056 RUB (c212). Results 
were sensitive to unit cost of inpatient-day (25% increase leads to cost-saving in with 
SAL/FP arm). Indirect cost inclusion lead to considerable cost-saving in with SAL/FP 
arm (7952 RUB = c209). CONCLUSIONS: Adding SAL/FP to routine treatment of 
severe and very severe COPD with Fen/IB is cost-effective.
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OBJECTIVES: To assess cost-effectiveness of SAL/FP vs. mono-ICS in different 
Russian regions using OPTIMA pharmacoeconomic model. METHODS: Description 
and calculation steps of OPTIMA model were published in ISPOR Twelfth Annual 
European Congress Research Abstract #PRS8. Variable region-speciﬁ c input data: 
drug prices and dosage proportion (from Farmexpert monitoring as of Q4 2009), 
medical tariffs (from regional government regulations), GDP per capita and average 
salary (from statistics service). Constant disease-speciﬁ c data: frequency of controlled/
uncontrolled asthma in arms (from clinical trial), number of unscheduled resources 
utilization and QoL in controlled and uncontrolled asthma (from prof. I.V.Demko’s 
observational study). Fixed combination SAL/FP (Seretide) was compared with mono-
ICS (Beclomethasone, Fluticasone and Budesonide). ICERs (cost per QALY) were 
assessed for each 84 Russian regions. Regional WTP was assumed as three regional 
GDP per capita. 1 EUR = 38 RUB. RESULTS: Weighted average monthly pharmaco-
therapy cost varied from 1410RUB (in Kostroma) to 3376RUB (in Tula) for SAL/FP, 
and from 430RUB (in Kostroma) to 1524RUB (in Khanty-Mansi) for MonoICS. The 
differences were driven by proportion of low/medium/high doses. Medical tariffs 
varied dramatically as well: tariffs of outpatient visit varied from 107RUB (in Ivanovo 
and Dagestan) to 975RUB (in Yamal-Nenets), bed-day cost varies from 500RUB (in 
Kurgan) to 3123RUB (in Yamal-Nenets). GDP per capita were from 38110RUB (in 
Ingush) to 928374RUB (in Tyumen); average salary—from 9 125 RUB (in Dagestan) 
to 46480RUB (in Yamal-Nenets). SAL/FP was cost-saving (dominating) in 18 regions, 
cost-effective in 62 regions (ICER < WTP; in this regions ICERs were from 3210RUB 
(84EUR) to 639480RUB (16828EUR) per QALY), and disadvantageous (ICER > 
WTP) in 4 regions (Ivanovo, Kabardino-Balkaria, Ingush, and Dagestan; mainly due 
to low WTP). CONCLUSIONS: In general case SAL/FP was cost-effective in most 
Russian regions, in some regions SAL/FP was cost-saving, and in few regions—not 
cost-effective. To assess cost-effectiveness in particular cohort of patients additional 
analyses are needed.
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OBJECTIVES: To analyze the eﬁ ciency of three alternative treatments (inhaled ilo-
prost (ILO), intravenous epoprostenol (EPO) and subcutaneous treprostinil (TRE)) for 
patients suffering from pulmonary arterial hipertensión (PAH) iniciating therapy with 
a prostanoid. METHODS: A Markov model was built to simulate a PAH patient 
cohort in functional class III of the New York Heart Association (NYHA). The model 
had four health states, those of the functional classes, plus death. Treatment changes 
were allowed when patients worsened from class III to IV. Time horizon was three 
years and transition cycles were of 12 weeks. Perspective was that of the National 
Health System (NHS) in Spain. Data sources were: 1) literature review, 2) costs 
databases and 3) expert opinion. Costs were expressed in euros 2009. Costs and effects 
were discounted at a 3% rate following Spanish recommendations. Both, deterministic 
and probabilistic analyses were performed to check for robustness of results. 
RESULTS: At three years, results for initiating prostanoid therapy with ILO, EPO and 
TRE were, respectively: total cost—c143,092, c430,271 and c360,387 -; efﬁ -
cacy—2.695 LYG, 2.729 LYG and 2.690 LYG -; —1.737 QALY, 1.780 QALY and 
1.728 QALY -; mean cost per LYG—c53,092, c157,678 and c133,997; mean cost 
per QALY—c82,376, c241,667 and c208,595 -. Incremental cost-effectiveness ratios 
and cost-utility ratios of EPO vs. ILO were: >8.5Mc/LYG and >6.5Mc/QALY, and 
vs. TRE were: >1.5Mc/LYG y > 1.3 Mc/QALY, much above the usually accepted 
threshold in Spain of 30,000 c/LYG or QALY. ILO was dominant vs. TRE. Sensitivity 
analyses conﬁ rmed these results. CONCLUSIONS: Initiating prostanoid therapy in 
class III PAH patients with intravenous epoprostenol is slightly more efﬁ cacious than 
the alternatives. At a three-year time horizon, inhaled iloprost shows to be the less 
costly alternative for the NHS in Spain.
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OBJECTIVES: To investigate if easily accessible pre-screening of individuals at risk 
for COPD leads to a more accurate selection of patients for ordinary spirometry, 
thereby improving the incidence of pathological test results. METHODS: Primary care 
